Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Maze Therapeutics
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Alloy raises $75m in venture funding to further its mission of open-source antibody technology discovery. It also spins out portfolio companies, like ophthalmic-focused Broadwing.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.
- Gene Therapy, Cell Therapy
Drug Discovery Tools